Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma

BACKGROUND: Previously reported results of phase 2 and phase 3 trials showed a significant improvement in the rate of objective response and progression-free survival with nivolumab (anti-PD-1 antibody) plus ipilimumab (anti-CTLA-4 antibody) vs ipilimumab alone in patients with advanced melanoma. To...

Full description

Saved in:
Bibliographic Details
Published in:Lancet Oncol
Main Authors: Hodi, F Stephen, Chesney, Jason, Pavlick, Anna C, Robert, Caroline, Grossmann, Kenneth F., McDermott, David F, Linette, Gerald P, Meyer, Nicolas, Giguere, Jeffrey K, Agarwala, Sanjiv S, Shaheen, Montaser, Ernstoff, Marc S, Minor, David R, Salama, April K, Taylor, Matthew H, Ott, Patrick A, Horak, Christine, Gagnier, Paul, Jiang, Joel, Wolchok, Jedd D, Postow, Michael A
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630525/
https://ncbi.nlm.nih.gov/pubmed/27622997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30366-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items